Dr. Kristen Buck
everyone. and morning, Thank you, good James,
that scientific body a built follow pipeline Lisata's is of technology and grounded of published portfolio us preclinical proprietary and data. those patented know, and rationale on a early in clinical that is As strong
technology is major in to treatment We the platform designed context increasing the system. our tumors platform importance the pressures of and advance to Our health address of care critical impediments provide tumors combination our do. with of meaningful on data lead of appreciate that you we has for the of assure product solid overview advanced other will top I solid of pharmacoeconomic successful our candidate, anticancer agents. clinical an mind the generating everything LSTAX, technology, can in entire that, this goal organization With now advanced I LSTAX, in treatment to
of tumors. effective many it surrounded stroma the fact patient's cancer. in and of therapies solid negatively effectively tumor a remain pancreatic The defines cancers the maximizing in advances most the many tissue as cancer cancers. only safety with microenvironment hostile challenge today, to effectiveness a tumor anticancer difficult therapy efficient as TME, cancer, and solid tumor solid coupled major gastric Despite to treat combination in makes of fibrotic the are on cancer these not cancers access the dense less the This the which such which effectively are immunotherapies of suppresses tumors cytotoxic fighting pharmacotherapies microenvironment, known also system Stroma, that in impacts of agents and to ability treat. targeting a treatment other dense most hostile by Many or tissue and the limit Cancers, tumor. exhibit immune tumors
while well beta X-amino upregulated mechanism alpha and CendR combat beta CendR the microenvironment peptides as its product cells tumor targets active a through deliver Protease To expressed candidate, LSTAX integrins, to having tumor. and these is once approach the drugs on to potential in Lisata's based the less cyclic is themselves drug that investigational naturally on an transport or fragment in modify internalizing microenvironment cleaved also it transport immunosuppressive. these the anticancer cells a activate LSTAX system actuates called acid the Fragment. into make to not the on protease. but are vascular C-end selectively RGD peptide affinity the that stroma occurring endothelial CendR the healthy tumor tumor five tumor tissue. this, cells is release by rule, is is and lead integrins found as system, active three Lisata's LSTAX a v for that to
to cells to tumor fragment anticancer high drugs solid active for receptor CendR has then and on rule transport bury the C-end affinity binds adjacent called an Cend neuropilin-X and The activate endothelial also more into tumor tumors. and pathway efficiently upregulated
been and modify subject delivery around pancreatic have cancer. the results the efficacy and scientific LSTAX RNA-based of of data, models come the from of demonstrated significant enhance tolerability LSTAX tumor adding enhanced standard of tumors. and a and therapeutics. Along in a Additionally, have research against favorable of and internally has amassed solid preclinical over immunotherapy nonclinical our immune to anticancer and patients hostile it to cells drugs the world XXX microenvironment, with with collaborators to chemotherapy anticancer making to metastatic used less These of of groups Lisata safety, care emerging been we publications. has one from Clinically, range for demonstrating delivery activity therapy, shown including collaborators, range
of subject are treatment the clinical dozen solid for in modality globally the tumors. active exploit of development treatment a LSTAX a for is to range to about various potential of Our a tumors. solid the LSTAX anticancer designed Currently, enhance of of programs plans variety trials
these of led few Australasian at The in trial with Gastro-Intestinal clinical to being double-blind, trial adenocarcinoma. XXX Zealand Group gemcitabine randomized, individually. at NHMRC XX University Sydney. of the combination trial nab-paclitaxel pancreatic metastatic and is a patients, with ductal evaluating and on ASCEND in trial Australia touch me with up in placebo-controlled LSTAX AGITG, the Let is center a Cancer clinical by The the sites conducted New Trials in collaboration or patients
enrollment XXXX. completion second the projected originally by quarter of We
than with achieve sooner we in XX% However, study nearly last that. the enrolled, patient could
combination in with first-line the planned we, recently, our of evaluating along five trials non-resectable in with the Australia, of impact study that ductal include is locally trial Warpnine existing and durvalumab are the using treatment chemotherapy immunotherapies. partner, in iLSTAX chemotherapy a research is advanced in in first This on to of pancreatic LSTAX's and therapies expanding as LSTAX we first which treated gemcitabine immunotherapy adenocarcinoma. patients Just care our nab-paclitaxel standard clinical several
this enrollment We XXXX. also quarter expect trial of by completion the in second
basket now trial placebo-controlled Canada including is Europe, and The cytotoxins Enrollment IIa trial trial and Asia, and open. of with combination in esophageal Phase in a solid LSTAX head Company's cholangiocarcinoma. standards in is This of and care States, care. both United of evaluating neck, includes standards the LSTAX tumors, BOLSTER immunotherapy
unfortunately However, which to led price has gouging delays the severe by normally the shortage, and care in in many hundreds others, would long prices like any of we, suppliers of of is patients. some being times shortages cisplatin part standard reaching drug, This cisplatin resulting of by cholangiocarcinoma of available cost. regimen global are impacted obtaining for material the what
cisplatin, secured Despite these challenges, and of needs has trial, BOLSTER our expect this in and the a team hands material the patients of our sufficient to and in to identified our we protocol required sites, the available about this in one cholangiocarcinoma announcing -- Once arm. much component look patient to first requirement month. of within forward studies treated the we at this investigational Bolsters the supply is
trial, with enrolled. of Ib/IIa steady the with approximately to CENDIFOX a appendiceal folfirinox study progress cancers. LSTAX colon in the neoadjuvant is Next pancreatic, in combination of It based trial open-label continues and XX% therapies Phase make
fourth We with year in expect the enrollment XXXX. of completion data this readout quarter by
also long-term territory, Phase with by licensee outcome trial trial in treatment data This with as Ib/IIa being Qilu well open-label provide evaluated open nab-paclitaxel currently will that in in and our in us trial is a biopsy post data. combination -- Pharmaceutical. led LSTAX immuno-profiling gemcitabine China, as
proof-of-concept, Pharmaceutical trial findings presented with abstract pancreatic the are ductal conducted in an Qilu from previously adenocarcinoma. data Phase the corroborated of reported in During LSTAX gemcitabine data Final the and patients study, the initiation our with WARPNINE. preliminary of of Australia Annual adenocarcinoma, first-line Phase Ib/IIa by XXXX iGoLSTA, nivolumab expected by and partner, plus during and which ASCO Meeting, LSTAX of is safety combination end the a second nab-paclitaxel FOLFIRINOX pending metastatic advanced in as from quarter as of funding evaluating a gastroesophageal locally early availability function a in XXXX. Ib/IIa non-resectable treatment studies, still efficacy
to related end hope the timing this by study of the quarter year. execution third the We to update of have further on of the
Temozolomide LSTAX Estonia added placebo temozolomide matching I of is multiple patients and treated with Target trials Latvia, in the in we in up studies the and including mentioned, care also placebo with standard and Glioblastoma of first XX fourth to temozolomide to double-blind, This It known is Phase addition X:X, targeted ongoing to evaluating GBM. the Multiform. have next plan of Multiforme, be In will when in months, study standard commonly other standard running and quarter patients as few LSTAX in placebo-controlled LSTAX in versus clinical to designed plus patient plus across a enroll randomized it with is of as diagnosed versus study Glioblastoma proof-of-concept combination IIa newly sites of LSTAX conducted for care. the care XXXX. just randomization
and orphan designation Drug medical recognizes of LSTAX been patients Importantly, has the and benefit by glioma. Administration potential indication. by not to granted U.S. LSTAX this recently highlights for the FDA announced, action as malignant also unmet only the This need but Food in
and a unblinded administer patients Phase cancer tolerability cytoreductive colorectal, controlled and of determine that intraperitoneal cancers will a randomized in The to contiguous delivered single-center to primary combination commonly in as and on as surgery study intraoperative appendiceal I along as currently the colorectal lavage HIPEC, trial the the a peritoneal be planning cancer or result undergoing intraperitoneal of ovarian study metastasis carcinomatosis, HIPEC. ovarian, are hyperthermic such to referred peritoneal we of LSTAX for via Lastly, or appendiceal with chemotherapy develops spread intraperitoneal safety with layer. in LSTAX,
XX with up alone first the and that be of surgery. receive total treated this will be randomized being shortly fourth and quarter in cytoreduction thereafter. LSTAX patients also running will versus anticipate X:X to patient We HIPEC XXXX study after the HIPEC
presentation description website. our section is in those a corporate For the of on are trials who more Appendix on interested, the our complete available
call body Dave. in of will I data two With slides for the Additionally, timing the there are of the anticipated key readouts clients. execution that milestone milestones back the presentation, and displays the now to that, turn
